Corvus Pharmaceuticals, Inc. just filed a prospectus, suggesting it plans to soon issue some securities

Corvus Pharmaceuticals, Inc. just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

USE OF PROCEEDS

 

We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50,000,000 from time to time. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Jefferies as a source of financing. We intend to use the net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, increasing our working capital and funding research and development and capital expenditures including clinical program progression.

 

The amounts and timing of our actual expenditures will depend on numerous factors, including our development and commercialization efforts with respect to our product candidates, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds, if any, from this offering in short-term, investment-grade, interest-bearing securities.

 

S-13

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback